Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

FDA grants Response Biomedical a Special 510(k) clearance for the RAMP Influenza A/B Assay

Response Biomedical Corporation announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company’s RAMP® Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens.

22 Oct 2009

Highlights of Cell Therapeutics' pixantrone study to be presented at the Lymphoma and Myeloma Conference

Cell Therapeutics, Inc. announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.

22 Oct 2009

Lake Health opens TriPoint Medical Center in Concord Township

Lake Health, formerly Lake Hospital System, today is celebrating the grand opening of its $155 million TriPoint Medical Center in Concord Township. A state-of-the-art digital hospital, TriPoint Medical Center is redefining the health care experience for patients, families and the community.

22 Oct 2009

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

St. Jude Medical's quadripolar pacing system receives European CE Mark approval

St. Jude Medical, Inc. today announced it has received European CE Mark approval for the industry’s first quadripolar pacing system for cardiac resynchronization therapy defibrillators (CRT-Ds). The quadripolar system offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

21 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Menarini granted exclusive European licence rights to Ipsen's Adenuric

Ipsen, an innovation-driven global specialty pharmaceutical group, announced an agreement whereby Ipsen grants the Menarini Group the exclusive licence rights to Adenuric® (febuxostat) in 41 countries. Ipsen retains co-promotion rights for Adenuric® in France.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

New mathematical model for rapid and accurate diagnoses of AHF

Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients

19 Oct 2009

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Readmission to a hospital after standard surgical treatment for colon cancer is far more common than suspected for elderly patients according to researchers who presented their findings at the 2009 Clinical Congress of the American College of Surgeons. Results from the first study to determine nationwide readmission rates following colectomy [surgical removal of malignant disease and part of the colon] in the Medicare population revealed that nearly one in nine patients over the age of 65 was readmitted within 30 days.

19 Oct 2009

Study reveals the cost effectiveness of Rheos blood pressure lowering device

A study conducted by the University of Rochester Medical Center demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.

19 Oct 2009

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Galapagos NV announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the development of new therapies for atherosclerosis.

14 Oct 2009

Five principles recommended by Iowa Committee for high-value health care

The Iowa Committee for Value in Healthcare today issued a report on five key principles for high-value, fiscally responsible health care that Congress and the Obama administration should consider as they continue discussions over national reform.

13 Oct 2009

CIGNA and Prohealth Physicians to implement an enhanced care coordination program

CIGNA and ProHealth Physicians, Inc., have expanded their longstanding relationship by implementing an enhanced care coordination program that includes pay-for-performance provisions and many of the features of a patient-centered medical home program. This is the first program of its kind in Connecticut.

9 Oct 2009

Mitraclip is an experimental and controversial procedure, says heart specialist

Seventy-seven year-old Hollywood legend Elizabeth Taylor announced on Tuesday she was having a Mitraclip heart procedure. Leading cardiothoracic surgeon and heart surgery expert Dr. Lishan Aklog, M.D. appeared on EmpowHer, the home of women's health online, to explain why her surgery is "experimental and controversial."

8 Oct 2009

Susquehanna Health acquires a Daxor blood volume analyzer

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Susquehanna Health of Williamsport, Pennsylvania. This will provide Susquehanna Health with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume.

8 Oct 2009

For one senior, Medicaid provides model care

Also as part of the "Are You Covered?" series, NPR's Jeff Brady profiles Gracie Scarrow, 94. She was diagnosed with congestive heart failure she didn't have the money to pay for the care she needed.

7 Oct 2009

First Edition: October 6, 2009

Kathy Young, the veteran benefits administrator for a large plumbing supply company headquartered in Madison, Wis., is well versed in the often fiendish complexities of medical bills (Kaiser Health News and The Washington Post).

6 Oct 2009

HeartWare International receives approval to expand its clinical sites

HeartWare International, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to expand the number of clinical sites participating in its U.S. bridge-to-transplant trial, known as the ADVANCE trial.

6 Oct 2009

Orphan drug designation for pixantrone applied by Cell Therapeutics

Cell Therapeutics, Inc. ("CTI") announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL.

30 Sep 2009